Related Experiment Video
Updated: Aug 15, 2026

Quantifying Glomerular Permeability of Fluorescent Macromolecules Using 2-Photon Microscopy in Munich Wistar Rats
Published on: April 17, 2013
Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy
L J Reichert1, R A Koene, J F Wetzels
1Department of Medicine, University Hospital Nijmegen, Netherlands.
Abstract:
In patients with membranous nephropathy, treatment should be limited to those at risk for disease progression. Urinary beta 2-microglobulin excretion was measured in 30 patients with membranous nephropathy, a nephrotic syndrome, and normal renal function (endogenous creatinine clearance > 80 mL/min), who were subsequently monitored for a median of 48 months. Renal function deteriorated in 11 of the 14 patients with a beta 2-microglobulin excretion > 500 ng/min and in only 2 of the 16 patients with a beta 2-microglobulin excretion < or = 500 ng/min (P < 0.001). The measurement of urinary beta 2-microglobulin excretion thus contributes to the identification of patients with membranous nephropathy at high risk for developing renal insufficiency and may provide guidance for early immunosuppressive treatment.
Insights
Urinary beta 2-microglobulin levels can identify membranous nephropathy patients at high risk for kidney function decline. This biomarker aids in guiding early immunosuppressive treatment for better outcomes.
Area of Science:
- Nephrology
- Biomarker Discovery
Background:
- Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults.
- Identifying patients at risk for progressive renal disease is crucial for appropriate treatment decisions.
Purpose of the Study:
- To evaluate the utility of urinary beta 2-microglobulin (β2M) excretion as a predictor of renal function decline in patients with membranous nephropathy.
- To determine if urinary β2M levels can guide early immunosuppressive therapy in MN.
Main Methods:
- Prospective monitoring of 30 patients with MN and normal renal function (creatinine clearance > 80 mL/min).
- Measurement of urinary β2M excretion at baseline.
- Median follow-up duration of 48 months.
Main Results:
- Renal function deteriorated in 11 out of 14 patients (78.6%) with urinary β2M excretion > 500 ng/min.
- Only 2 out of 16 patients (12.5%) with urinary β2M excretion ≤ 500 ng/min experienced renal function decline (P < 0.001).
Conclusions:
- Urinary β2M excretion is a significant predictor of renal insufficiency in membranous nephropathy patients.
- Elevated urinary β2M levels (> 500 ng/min) identify individuals who may benefit from early immunosuppressive treatment.
Related Concept Videos
Renal Drug Excretion: Glomerular Filtration
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles.
Renal Drug Excretion: Tubular Secretion
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Nephrotic Syndrome II : Assessment and Medical Management

